Gluvilda 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by enhancing the incretin system, thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. This dual action helps to improve glycemic control without causing significant hypoglycemia. Gluvilda 50 is indicated as monotherapy in patients inadequately controlled by diet and exercise alone, or as combination therapy with other antidiabetic agents such as metformin, sulfonylureas, or insulin when additional glycemic control is required. The medication is generally well tolerated, with a low risk of weight gain and hypoglycemia compared to other antidiabetic drugs. Common adverse effects may include headache, dizziness, and gastrointestinal disturbances, though serious adverse reactions are rare. It is important to monitor renal function periodically, as dose adjustments may be necessary in patients with renal impairment. Gluvilda 50 should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring to achieve optimal therapeutic outcomes.